STOCK TITAN
  1. Home
  2. Sec-filings
  3. PODD
  4. [8-K] INSULET CORP Reports Material Event

Insulet (PODD) explains 29 serious events vs 476 FDA device reports

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Insulet Corporation furnished an update and clarification related to its voluntary Medical Device Correction. The Company previously reported 18 Serious Adverse Events and later expanded communications on April 10, 2026 to include 13 expired lots, stating this does not change its earlier estimated financial impact. The updated communication referenced 29 confirmed Serious Adverse Events. The Company also explained that an FDA website statement citing 476 serious injuries actually refers to 476 Medical Device Reports potentially related to the correction, rather than 29 confirmed Serious Adverse Events. The information is furnished under Item 7.01 and is not deemed filed under the Exchange Act.

Positive

  • None.

Negative

  • None.

Insights

Insulet clarifies safety-report numbers without changing its stated financial impact.

Insulet provides more detail around its voluntary Medical Device Correction by distinguishing between confirmed Serious Adverse Events and broader Medical Device Reports referenced by the FDA. This distinction helps separate verified clinical outcomes from a wider pool of potentially related reports.

The Company now cites 29 confirmed Serious Adverse Events, while confirming that the FDA’s 476 figure represents Medical Device Reports potentially tied to the issue. It also states that adding 13 expired lots to the communication does not alter its previously communicated estimated financial impact.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Initial Serious Adverse Events 18 reports Reported in March 12, 2026 press release
Additional expired lots 13 lots Added in April 10, 2026 customer communication
Confirmed Serious Adverse Events 29 events Stated in updated communication
Medical Device Reports 476 reports Figure referenced by FDA as of April 17
Medical Device Correction regulatory
"issued and filed with the SEC a press release regarding a voluntary Medical Device Correction"
A medical device correction is an action taken by a manufacturer or regulator to fix a safety or performance problem in an already-distributed medical device, such as a repair, software update, label change, or retrofit. It matters to investors because corrections can signal safety risk, trigger costs, regulatory scrutiny, lost sales or reputational damage—similar to a software patch or auto recall that interrupts normal business and may affect future revenue and liability exposure.
Serious Adverse Events medical
"the Company reported that it had received 18 reports of Serious Adverse Events"
Serious adverse events are significant problems or negative outcomes that occur during a medical treatment or clinical trial, such as severe side effects, hospitalizations, or life-threatening conditions. They matter to investors because such events can impact a company's reputation, lead to regulatory scrutiny, or delay the development of new products, ultimately affecting the company’s financial performance.
Medical Device Reports regulatory
"referring to 476 Medical Device Reports potentially related to the Medical Device Correction"
Item 7.01 regulatory
"The information in this Item 7.01 shall not be deemed “filed”"
Understanding 8-K Material Events →
0001145197FALSE00011451972026-04-292026-04-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(D) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  April 29, 2026
 
INSULET CORPORATION
(Exact name of registrant as specified in its charter)

Delaware001-3346204-3523891
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
100 Nagog Park
ActonMassachusetts01720
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:
(978)600-7000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐



Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value Per Share
PODDThe NASDAQ Stock Market, LLC


Item 7.01Regulation FD Disclosure
On March 12, 2026, Insulet Corporation (the “Company”) issued and filed with the SEC a press release regarding a voluntary Medical Device Correction. In that press release, the Company reported that it had received 18 reports of Serious Adverse Events.

On April 10, 2026, the Company updated communications to customers and posted on its website information regarding this device correction. This updated communication included the addition of 13 expired lots. The addition of these expired lots has no impact on the Company’s previously communicated estimated financial impact. The communication also noted 29 confirmed Serious Adverse Events.

On April 29, 2026, the U.S. Food and Drug Administration (FDA) included language on their website that said “As of April 17, Insulet has reported 476 serious injuries and no deaths associated with this issue”. The Company confirmed that the FDA statement is referring to 476 Medical Device Reports potentially related to the Medical Device Correction rather than the 29 confirmed Serious Adverse Events.

The information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

Item 9.01Financial Statements and Exhibits
(d)Exhibits.
No.Exhibit
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.
 
  INSULET CORPORATION
April 29, 2026  By:/s/ John W. Kapples
Name:John W. Kapples
Title:Senior Vice President, General Counsel

Source: View Original Filing on SEC EDGAR

FAQ

What did Insulet (PODD) disclose about its voluntary Medical Device Correction?

Insulet disclosed an update and clarification on its voluntary Medical Device Correction. It reiterated earlier information, expanded communications on April 10, 2026, and clarified how its confirmed Serious Adverse Events relate to a larger set of Medical Device Reports referenced by the FDA.

How many Serious Adverse Events has Insulet (PODD) confirmed?

Insulet referenced 29 confirmed Serious Adverse Events related to the Medical Device Correction. This figure reflects cases the Company has confirmed, distinguishing them from a larger number of potentially related Medical Device Reports cited by the U.S. Food and Drug Administration.

What is the significance of the FDA’s reference to 476 serious injuries for Insulet (PODD)?

The FDA website language cited 476 serious injuries with no deaths. Insulet clarified that this figure represents 476 Medical Device Reports potentially related to the Medical Device Correction, rather than 29 confirmed Serious Adverse Events previously described in the Company’s communications.

Did Insulet’s (PODD) update on expired lots change its estimated financial impact?

No, Insulet stated that adding 13 expired lots in its April 10, 2026 communication does not affect its previously communicated estimated financial impact of the Medical Device Correction. The update changes the scope of lots discussed, not the Company’s earlier financial assessment.

Is Insulet’s (PODD) Medical Device Correction disclosure considered filed or furnished?

The information is furnished under Item 7.01 of the Exchange Act. Insulet specified that this information shall not be deemed filed for Section 18 liability and is not incorporated by reference into other Securities Act filings unless specifically referenced.

Filing Exhibits & Attachments

3 documents

Other Documents